(Q38023589)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22759093%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

title

Adjuvant therapy in stage I carcinoma of the breast: the influence of multigene analyses and molecular phenotyping (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22759093%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22759093%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Beryl McCormick

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22759093%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

9

Shahla Masood

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22759093%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

3

Harold J Burstein

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22759093%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

5

Luigi Cataliotti

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22759093%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

15

Emiel J T Rutgers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22759093%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

2

Harry Bartelink

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22759093%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

author name string

Gordon F Schwartz

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22759093%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Blake Cady

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22759093%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Ian S Fentiman

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22759093%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Roland Holland

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22759093%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Juan A Palazzo

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22759093%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Peter I Pressman

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22759093%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Lajos Pusztai

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22759093%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Andrew D Seidman

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22759093%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Lawrence J Solin

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22759093%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Joseph A Sparano

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22759093%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Jorge Reis-Filho

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22759093%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

language of work or name

1 reference

1 July 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22759093%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22759093%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22759093%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22759093%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

page(s)

303-311

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22759093%20AND%20SRC:MED&resulttype=core&format=json

Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer

6 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-4741.2012.01264.X

Predictive algorithms for adjuvant therapy: TransATAC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-4741.2012.01264.X

An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-4741.2012.01264.X

Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19-22, 2001, Philadelphia, Pennsylvania

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-4741.2012.01264.X

Routinely available indicators of prognosis in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-4741.2012.01264.X

Adjuvant chemotherapy in older women with early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-4741.2012.01264.X

Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-4741.2012.01264.X

Triple-negative breast cancer: role of specific chemotherapy agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-4741.2012.01264.X

Significance of E-cadherin expression in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-4741.2012.01264.X

Outcome after breast conservation treatment with radiation for women with triple-negative early-stage invasive breast carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-4741.2012.01264.X

Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-4741.2012.01264.X

Use of immunohistochemical markers can refine prognosis in triple negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-4741.2012.01264.X

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-4741.2012.01264.X

What is the difference between triple-negative and basal breast cancers?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-4741.2012.01264.X

Gene-expression signatures in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-4741.2012.01264.X

Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-4741.2012.01264.X

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-4741.2012.01264.X

Predicting a local recurrence after breast-conserving therapy by gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-4741.2012.01264.X

Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-4741.2012.01264.X

Development of the 21-gene assay and its application in clinical practice and clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-4741.2012.01264.X

Clinical application of the 70-gene profile: the MINDACT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-4741.2012.01264.X

Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-4741.2012.01264.X

Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-4741.2012.01264.X

Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-4741.2012.01264.X

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-4741.2012.01264.X

New molecular classifications of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-4741.2012.01264.X

Supervised risk predictor of breast cancer based on intrinsic subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-4741.2012.01264.X

Breast cancer subtypes and the risk of local and regional relapse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-4741.2012.01264.X

High-throughput genomic technology in research and clinical management of breast cancer. Exploiting the potential of gene expression profiling: is it ready for the clinic?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-4741.2012.01264.X